Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT01970475 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

526

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid

Interventions

BIOLOGICAL: ABP 501
BIOLOGICAL: Adalimumab

Sponsor

Amgen